Jon's Licence Portfolio
18F-FET-βAG-TOCA is a novel, ‘click’ 18F-labelled octreotate PET imaging radiopharmaceutical that detects tumour lesions in patients with neuroendocrine tumours (NETs).
A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity
A simple, whole blood 2-gene expression signature that distinguishes bacterial infection from both viral infection and childhood inflammatory diseases.
DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway
A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging
A tool for predicting Alzheimer’s Disease (AD) with greater accuracy than conventional methods.
A tool for predicting survival outcomes in patients with pulmonary hypertension with greater accuracy than doctor’s measures
Patient Metabolic profiling for personalised medicine.
Gene expression for tuberculosis diagnosis
Small molecule inhibitors for treatment of solid tumours